Incidence of diabetes and ischemic heart disease in COVID-19 post pandemic

Amrendra Kumar Singh; Raj Kamal Choudhary; Kumari Ragini; Anjum Perwez

doi:10.18203/2320-6012.ijrms20233698

Authors

Amrendra Kumar Singh Department of Medicine, J. L. N. M. C. Bhagalpur, Bihar, India
Raj Kamal Choudhary Department of Medicine, J. L. N. M. C. Bhagalpur, Bihar, India
Kumari Ragini Department of Obstetrics and Gynaecology, A. N. M. C. H. Gaya, Bihar, India
Anjum Perwez Department of Medicine, J. L. N. M. C. Bhagalpur, Bihar, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20233698

Keywords:

Prevalence, Post COVID-19, CVD, DM

Abstract

Background: The long-term effects of COVID-19 pandemic are currently getting more attention. The majority of individuals with COVID-19 report having symptoms for longer than 4 weeks following their initial appearance. after COVID-19 infection, there is worry that cardiovascular conditions and metabolic conditions may be harmed. Aim of the study the incidence of ischaemic heart disease and diabetes mellitus (DM) post COVID 19 pandemic.

Methods: Information for all individuals diagnosed as suffering of COVID-19 were taken at the beginning of the investigation from the health department's release of electronic medical records in February 2021. The main outcomes analysed were first ever documented cardiovascular disorders (CVD) as well as DM diagnoses. The data were then combined for the time periods following the index date (long COVID-19), for five to twelve weeks following the index date (post-acute COVID19), for four weeks after the date of indexing (acute COVID-19), prior to the index date (Pre-index). For COVID-19 patients as well as control subjects, incidence rates with precise Poisson confidence intervals (CIs) were computed.

Results: CVD events was 1362 in COVID-19 study group while it was 131 in control study group at phase corresponding to four weeks after the indexed date. CVD events was 781 in COVID-19 study group while it was 298 in control study group at phase corresponding to five to twelve weeks since the date of indexing. CVD events was 781 in COVID-19 study group while it was 298 in control study group at phase corresponding to five to twelve weeks since the date of indexing. CVD events was 2,134 in COVID-19 study group while it was 298 in control study group at phase corresponding to 13 to 52 weeks since the date of indexing.

Conclusions: Early on after COVID-19 infection, the risk of CVD is elevated, and this risk is elevated for up to three months. However, there does not appear to be a long-term rise in the prevalence of CVD or DM in COVID-19 patients who do not already have these illnesses. This study shows that after COVID-19 infection, the incidence of DM is high for at minimum 12 weeks before it starts to decline.

Metrics

Metrics Loading ...

References

Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID-mechanisms, risk factors, and management. BMJ. 2021;374:n1648.

Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis. 2020;29:104949.

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE et al. Factors associated with COVID-19-related death using Open Safely. Nature. 2020;584:430-36.

Magadum A, Kishore R. Cardiovascular manifestations of COVID-19 infection. Cells. 2020;9:2508.

Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-64.

Hendren NS, Drazner MH, Bozkurt B, Cooper LT. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020;141:1903-14.

Rey JR, Caro-Codón J, Rosillo SO, Iniesta AM, Castrejón-Castrejón S, Marco-Clement I. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020;22:2205-215.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.

Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al. Association of Cardiac Injury with Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802-10.

Katsoularis I, Fonseca-Rodríguez O, Farrington P, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021;398:599-607.

Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract. 2020;167:108382.

Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab. 2020;22:1935-41.

Reddy PK, Kuchay MS, Mehta Y, Mishra SK. Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature. Diabetes Metab Syndr. 2020;14:1459-62.

Papachristou S, Stamatiou I, Stoian AP, Papanas N. New-Onset Diabetes in COVID-19: Time to Frame Its Fearful Symmetry. Diabetes Ther. 2021;12:461-4.

Maddaloni E, Buzzetti R. COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020:e33213321.

Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment. Int J Mol Sci. 2020;21:3377.

Public Health England. Coronavirus (COVID-19) in the UK. UK summary. London: Public Health England, 2021. Available at: https://coronavirus. data.gov.uk/. Accessed on 27 July, 2023.

Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 2 September 2021. London: Office for National Statistics, 2021. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2september2021.Accessed. Accessed on 23 September, 2023

Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long-term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136.

Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S et al. Association of COVID-19 with arterial and venous vascular diseases: a population-wide cohort study of 48 million adults in England and Wales. MedRxiv. 2021:2021.11.22.21266512.

Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48:1740-40.

Imkampe AK, Gulliford MC. Trends in Type 1 diabetes incidence in the UK in 0- to 14-year-olds and in 15- to 34-year-olds, 1991-2008. Diabet Med. 2011;28:811-4.

Zakeri R, Bendayan R, Ashworth M, Bean DM, Dodhia H, Durbaba S et al. A case-control and cohort study to determine the relationship between ethnic background and severe COVID-19. E Clin Med. 2020;28.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373-83.

Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam. Pract. 2010;11:1.

Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728-9.

Holford TR. The Analysis of Rates and of Survivorship Using Log-Linear Models. Biometrics. 1980;36:299-305.

Williams R, Jenkins DA, Ashcroft DM, Brown B, Campbell S, Carr MJ et al. Diagnosis of physical and mental health conditions in primary care during the COVID-19 pandemic: a retrospective cohort study. Lancet Public Health. 2020;5:e543-50.

Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626-31.

Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773.